MOTS-c: The tiny peptide encoded inside mitochondrial DNA

MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene. That fact alone is worth lingering on: the mitochondrial genome is not only a set of respiratory-chain instructions. In 2015, Lee, Cohen, and colleagues reported in Cell Metabolism that MOTS-c could be detected in circulation, that it engaged AMPK-linked metabolic pathways, and that it improved insulin sensitivity in high-fat-diet mice. Mouse metabolic work is a starting point — and a genuinely unusual one, given where the peptide is encoded.

Where the human story stands

There is no FDA-approved MOTS-c drug. Reviews in 2023 still describe therapeutic exploitation as a prospect, not a label. Zheng et al. (Frontiers in Endocrinology, PMC9905433) summarize glucose-metabolism and aging-adjacent findings and, correctly, stop short of treating those findings as a finished human dosing literature. A MOTS-c analog has appeared in clinical-trial registries for metabolic indications; an analog in a registry is still a different object from a research-storefront vial.

In July 2026, FDA’s Pharmacy Compounding Advisory Committee listed MOTS-c related bulk substances alongside BPC-157, KPV, and TB-500. That grouping is a useful signal: the Agency is being asked, in public, whether these sequences belong in compounded human drugs. Until a list decision and a lawful compounding pathway exist, a research chemical remains a research chemical — which is still a perfectly interesting thing to study.

A peptide written in mitochondrial DNA is a small molecular surprise — and still only as strong as the experiments behind it.